News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Warns of Birth Defects with Use of Johnson & Johnson’s Topamax
March 7, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, U.S. health officials said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Drug pricing
9 midsize drugmakers climb aboard Trump’s MFN train
September 1, 2026
·
2 min read
·
Tristan Manalac
Legal
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
August 31, 2026
·
2 min read
·
Annalee Armstrong
Vaccines
Kennedy questions vaccination guidelines following Trump’s order to break up MMR
August 24, 2026
·
2 min read
·
Tristan Manalac
Policy
Lawmakers urge FDA to enact new China policies after 3 gene therapy trial deaths
August 21, 2026
·
4 min read
·
Gabrielle Masson